small molecule

VIVLODEX

MELOXICAM

Loss of exclusivityMarch 2035latest FDA-listed patent expiry
CompanyICEUTICA OPERATIONS LLC

Drug detail

Brand nameVIVLODEX
Active ingredientMELOXICAM
Strength10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalOctober 2015
Marketing statusDISCN

Listed patents

PatentExpiresType
9808468March 2035use U-2165
9649318March 2035product
9526734March 2033product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

VIVLODEX patent cliff — loss of exclusivity March 2035 | CliffBio